Search

everythinglearnresearchcommunity

for

Search:↓

Some breast cancer patients on hormone therapy experience hair loss, and treatments like certain topical inhibitors and supplements may help without harming their cancer prognosis.

Hair loss from hormone therapy in breast cancer patients can be improved with minoxidil treatment.

The NAMS 2014 recommendations guide healthcare providers on treating health issues in midlife women, emphasizing individualized care and informed decision-making.

Topical estrogen treatments did not change hair growth in certain mouse strains, questioning previous findings on their role in hair growth control.

Minoxidil helps treat eyebrow thinning, monilethrix, early hair loss, and shortens chemo-related hair loss.

Nanoemulgel improves hair growth and quality using finasteride without irritation.

A woman kept her eyelashes during chemotherapy possibly because of her glaucoma eye drops.

Chemotherapy causes hair loss starting soon after treatment begins and recovers about 3 months after ending, while tamoxifen does not significantly affect hair growth.

Chemotherapy can cause significant hair thinning and changes in hair texture, while tamoxifen has a smaller effect.

Hair and scalp pain is more common and severe in breast cancer patients on chemotherapy than those on tamoxifen.

Hair loss is a common but often unreported side effect of cancer treatments, especially for breast and prostate cancers.

Topical drugs and near-infrared light therapy show potential for treating alopecia.

The topical inhibitor CUR61414 was not effective in treating basal cell carcinoma in human trials.

FAGA diagnosis uses blood tests and trichoscopy, with treatments like topical minoxidil, oral anti-androgens, and hormone-modulating drugs.

Topical minoxidil helps treat female pattern hair loss, but more research needed for other treatments.

Topical finasteride is an effective and safer treatment for male hair loss.

Some breast cancer patients on hormonal therapy may develop male or female pattern hair loss, which can sometimes be improved with topical treatments.

The FDA warned about safety issues with remdesivir and tofacitinib, finasteride is linked to suicidality, potent topical corticosteroids increase osteoporosis risk, henna can cause hemolysis in G6PD deficiency, chemotherapeutic agents can cause adverse reactions, drug interactions are common in cancer patients, ketamine can reduce at-risk drinking, high dose of anticholinergics increases dementia risk in Parkinson's patients, and prenatal exposure to second-generation antipsychotics increases pregnancy complications.

The 2% minoxidil nanosuspension is as effective as the commercial product but safer and easier to use.

A breast cancer patient had lasting hair loss after chemotherapy, which improved with minoxidil treatment.

Breast cancer hormone therapy can cause hair loss, which can be treated with daily applications of specific topical solutions like minoxidil and hydrocortisone butyrate.

The document concludes that scalp cooling and treatments like minoxidil can help manage hair loss from cancer therapy.

Vitamin B supplements may reverse grey hair.

Estrogens can improve skin aging but carry risks; more research is needed on safer treatments.

Estrogens and SERMs can help with skin aging, but their safety and effectiveness need more research.

Hair loss requires customized treatments based on its various causes and types.

Nanostructured lipid carriers improve minoxidil delivery for hair loss treatment.

Antiandrogens are effective for conditions like prostate cancer and skin issues, but more research is needed to confirm their benefits and minimize side effects.

The conclusion is that proper evaluation and treatment of hair loss in midlife women is important, considering the emotional impact and potential for various treatments.

Over 50% of women over 50 experience hair loss, with minoxidil being the only proven effective treatment.